Nov 18, 2026
  • Pelabresib 144-week Phase III MANIFEST-2 data show sustained clinical effects in longest follow-up from a combination trial in first-line JAKi-naïve myelofibrosis
  • KISQALI® six-year NATALEE analysis deepens understanding of treatment outcomes across nodal subgroups in HR+/HER2- early breast cancer
  • SNV4818 (now RAE346) Phase I/II data mark first results since acquisition, reinforcing commitment to innovation in HR+/HER2- breast cancer through pan-mutant selective PI3Kα inhibition
  • SCEMBLIX® longer-term ASC4START and ASC2ESCALATE data reinforce efficacy and safety profile in earlier-line CML

East Hanover, November 18, 2026 – Novartis will present data from nearly 60 abstracts at the 2026 San Antonio Breast Cancer Symposium (SABCS) and 68th American Society of Hematology (ASH) Annual Meeting & Exposition. Together, the data reinforce Novartis leadership in breast cancer and hematology, spanning approved medicines and a promising pipeline of next-generation therapies.

At SABCS, two late-breaking abstracts will spotlight new breast cancer data. A NATALEE nodal analysis will add to the long-term evidence for Kisqali, while SNV4818, now RAE346, will mark its first clinical data presentation following acquisition from Synnovation. At ASH, eight oral presentations will feature Novartis medicines, including 144-week Phase III MANIFEST-2 results for investigational pelabresib.

“For people living with cancer and serious blood disorders, progress means continuing to push science forward in pursuit of outcomes that meaningfully impact patients’ lives,” said Andrea Myers, Global Head, Oncology Development, Ad Interim, Novartis. “The data we’re presenting at SABCS and ASH reflect that commitment, deepening our understanding of approved and investigational medicines while advancing new approaches rooted in disease biology.”

Key SABCS data highlights include:

Abstract Title

 

Abstract Number / Presentation Details

Kisqali® (ribociclib)

 

 

Six-year efficacy outcomes by nodal status from the NATALEE trial of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)

 

Abstract #P1-15-27

Late-breaking Poster

December 9, 12:30 – 2:00 pm CT

Prognostic and predictive value of key immunohistochemistry (IHC) protein biomarker expression levels in the NATALEE trial of adjuvant ribociclib (RIB) and nonsteroidal aromatase inhibitor (NSAI) in hormone receptor-positive/human epidermal growth factor receptor 2− early breast cancer (HR+/HER2− EBC)

 

Abstract #RF2-2

Rapid Fire Mini Oral

December 8, 5:30 – 6:30 pm CT

SNV4818 (now RAE346, acquired from Synnovation)

 

 

Initial clinical results from the first-in-human phase 1/2 study of SNV4818, a highly mutant-selective PI3Ka inhibitor, in patients (pts) with PIK3CA-mutated advanced cancers, including HR+/HER2− breast cancer

 

Abstract #P1-4-22

Late-breaking Poster

December 9, 12:30 – 2:00 pm CT

 

 

 

Key ASH data highlights include:

Abstract Title

 

Abstract Number / Presentation Details

Pelabresib (DAK539)

 

 

Long-term outcomes of pelabresib (PELA) plus ruxolitinib (RUX) in Janus kinase inhibitor (JAKi)-naive myelofibrosis (MF): Week 144 results from the phase 3 MANIFEST-2 study

 

Abstract #525

Oral

December 13, 10:00 – 10:15 am CT

Pelabresib monotherapy in high-risk essential thrombocythemia after hydroxyurea resistance or intolerance: Results from Arm 4 of the open-label, phase 2 MANIFEST study

 

Abstract #1038

Oral

December 14, 5:45 – 7 pm CT

Scemblix® (asciminib)

 

 

Sustained superior tolerability and patient-reported benefits with asciminib vs nilotinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the ASC4START trial

 

Abstract #801

Oral

December 14, 11:00 – 11:15 am CT

Week 96 interim analysis (IA) of efficacy and safety in the Phase 2 ASC2ESCALATE trial: Asciminib (ASC) in the first-line (1L) cohort of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)

 

Abstract #5507

Poster

December 14, 6:00 – 8:00 pm CT

Week 96 interim analysis (IA) of efficacy and safety results in the Phase 2 ASC2ESCALATE trial: Asciminib (ASC) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after 1 prior tyrosine kinase inhibitor (TKI)

 

Abstract #1987

Poster

December 12, 5:30 – 7:30 pm CT

Ianalumab (VAY736)

 

 

Immunologic biomarker analyses of ianalumab's mechanism in primary immune thrombocytopenia from the phase 3 VAYHIT2 trial

 

Abstract #1251

Poster 

December 12, 5:45 – 7 pm CT

Rapcabtagene autoleucel (YTB323)

 

 

Rapcabtagene autoleucel manufactured using the T-Charge™ platform preserves T cell stemness and overcomes immunosuppressive tumor microenvironments in R/R DLBCL

 

Abstract #436

Oral

December 12, 4:45 – 5:00 pm CT

Rapcabtagene autoleucel (YTB323) phase 2 trial in patients (pts) with first-line high-risk large B-cell lymphoma (1L HR LBCL): 1 year follow-up

 

Abstract #1922

Poster

December 12, 5:30 – 7:30 pm CT

Rapcabtagene autoleucel (YTB323) in third-line or later diffuse large B-cell lymphoma (DLBCL): Phase 2 clinical update

 

Abstract #3690

Poster

December 13, 6:00 – 8:00 pm CT

Fabhalta® (iptacopan)

 

 

Iptacopan demonstrates sustained hemolysis control in patients with paroxysmal nocturnal hemoglobinuria (PNH): 18-month follow-up in the APPULSE-PNH phase 3b trial

 

Abstract #3167

Poster

December 13, 6:00 – 8:00 pm ET

Pregnancy outcomes following iptacopan exposure in patients with paroxysmal nocturnal hemoglobinuria: A descriptive analysis

 

 

Abstract #3175

Poster

December 13, 6:00 – 8:00 pm ET

 

Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products.

Novartis in breast cancer 
For over 30 years, Novartis has been at the forefront of driving scientific advancements for individuals affected by breast cancer and enhancing clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipelines, Novartis leads the industry in discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease. 

Novartis in hematology
Our legacy in hematology runs deep, shaped by over 25 years of progress, partnerships and a commitment to keep asking questions, challenging norms and striving for better answers in a uniquely complex field. In the past two decades, we have delivered more than 10 medicines across more than 15 blood cancers and serious blood disorders including leading the era of targeted therapies in cancer and bringing the first CAR-T therapy to patients.

Innovation in hematology has brought significant progress, yet patients and clinicians continue to face persistent challenges. We’re forging the future of hematology, powered by our foundation in scientific discovery to deliver meaningful change for patients with unmet needs.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram US.

Novartis Media Relations
E-mail: [email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]